Publications by authors named "Mary Syto"

Claim this Profile
P
Pharmacokinetic Characterization of Cendakimab Administered with Different Devices and at Different Injection Sites in Healthy Participants.
Peijin Zhang, Claudia H M C De Oliveira, Kyungha Yu, Shenita Basdeo, Christina M Charriez, Mary Syto

Eur J Drug Metab Pharmacokinet· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiple-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites and the Pharmacodynamic and Pharmacokinetic Interactions with Pseudoephedrine, a Sympathomimetic Agent, in Healthy Subjects.
Jonathan Q Tran, Peijin Zhang, Susan Walker, Atalanta Ghosh, Mary Syto

Adv Ther· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites Alone and in Combination with Gemfibrozil, Itraconazole, or Rifampin in Healthy Subjects: A Randomized, Parallel-Group, Open-Label Study.
Jonathan Q Tran, Peijin Zhang, Atalanta Ghosh, Liangang Liu, Mary Syto

Adv Ther· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer.
Barbara J Gitlitz, Eric Bernstein, Edgardo S Santos, Greg A Otterson, Ginger Milne, Mary Syto

J Thorac Oncol· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarker-based phase I dose-escalation, pharmacokinetic, and pharmacodynamic study of oral apricoxib in combination with erlotinib in advanced nonsmall cell lung cancer.
Karen Reckamp, Barbara Gitlitz, Lin-Chi Chen, Ravi Patel, Ginger Milne, Mary Syto

Cancer· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis